
FDA Approves New RSV Vaccine for Individuals Aged 50-59
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved Arexvy, a vaccine designed to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), for …
FDA Approves New RSV Vaccine for Individuals Aged 50-59 Read More